Innovative tumour targeting therapeutics in Cushing's disease.

Vivian von Selzam, Marily Theodoropoulou

Journal: Best practice & research. Clinical endocrinology & metabolism 2022;36(6):101701

PMID: 36511278

Full Text on Elsevier Science View on PubMed

Abstract

Cushing's disease (CD) is the most frequent form of endogenous hypercortisolism. Management of this devastating condition relies on pituitary surgery, while effective pharmacological treatment mainly focus on periphery targeting pharmaceuticals. Approved tumour-targeting drugs are limited to dopamine agonists and somatostatin analogues with frequently low efficacy and substantial side effects. Discoveries on the genetics and pathophysiology of corticotroph tumorigenesis brought forward new potential pharmacological targets. Compounds such as retinoic acid although promising in preclinical studies, are not as efficient in the clinic. Others, such as, silibinin, gefitinib and roscovitine are effective in preclinical models, but their efficacy and safety still needs to be determined in patients with CD.

Address: Medizinische Klinik und Poliklinik IV, LMU Klinikum, Ludwig-Maximilians-Universität München, Munich, Germany.; Medizinische Klinik und Poliklinik IV, LMU Klinikum, Ludwig-Maximilians-Universität München, Munich, Germany. Electronic address: [email protected].

DOI: 10.1016/j.beem.2022.101701

Link outs

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, ACTH-Secreting Pituitary Adenoma, Adenoma, Pituitary ACTH Hypersecretion, Pituitary Gland, Somatostatin